Shilpa Medicare FY26 Revenue Surges 18% to ₹1,549 Crore, EBITDA Grows 30%
Shilpa Medicare reported FY26 revenue of ₹1,549 crore, up 18% YoY, and EBITDA of ₹445 crore, up 30% YoY. Q4 FY26 revenue was ₹439 crore (up 30% YoY) and EBITDA was ₹121 crore (up 40% YoY). Adjusted PAT for Q4 FY26 was ₹87 crore, a 147% YoY increase. The company highlighted strong growth across API, Formulation, and Biologics segments.
The announcement details robust financial results, including record revenues and EBITDA, along with significant growth percentages. This level of performance is material and likely to positively influence investor perception and stock performance.
The company reported strong financial performance with significant year-on-year growth in revenue, EBITDA, and adjusted PAT for both the quarter and the full fiscal year. Positive commentary from management and progress in key business segments further support a positive sentiment.
Shilpa Medicare Limited announced its investor presentation for the fourth quarter and financial year ended March 31, 2026. The company reported its highest-ever annual revenue of ₹1,549 crore, an 18% increase year-on-year, with EBITDA growing by 30% to ₹445 crore. The EBITDA margin improved by approximately 300 basis points to 29% YoY.
For the fourth quarter of FY26, Shilpa Medicare achieved its highest quarterly revenue of ₹439 crore, a 30% increase YoY, and its highest quarterly EBITDA of ₹121 crore, a 40% increase YoY. Adjusted Profit After Tax (PAT) for the quarter was ₹87 crore, a significant 147% increase YoY. The company highlighted strong operating leverage and improved EBITDA margins of 28% for the quarter.
Management commentary indicated a strong footing for FY26, with revenue growth of 18% and EBITDA growth of 30% YoY. The company is investing in R&D and manufacturing capabilities to build a differentiated portfolio and establish itself as a one-stop CDMO partner. The NorUDCA product for NAFLD is exceeding expectations, and the company is progressing regulatory filings for emerging markets. The international FDF business saw encouraging growth, with plans for transdermal patch launches in the EU and a submission to the USFDA completed. The API business remains a backbone, supporting FDF growth through vertical integration. The Biologics vertical is monetizing development and manufacturing capabilities through high-value collaborations, with co-development of two New Biological Entities (NBEs) and one New Chemical Entity (NCE).
The company also provided details on its business segments. The API business grew 16% YoY for both the quarter and the full year, driven by both Oncology and Non-Oncology segments. The Formulations business delivered its highest-ever quarterly and annual revenue, growing at approximately 54% YoY for the quarter and 30% YoY for FY26, boosted by the NorUDCA launch and strong EU formulations revenue. The Biologics segment is focused on a high-value biosimilars portfolio, with several programs advancing. The CDMO business covers a full spectrum of technologies, aiming to be a preferred one-stop outsourcing partner.
What to do with a filing like this
Shilpa Medicare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Shilpa Medicare Limited. Read the original for the full detail.